Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 138

Sort by

Sort Order Select

Journal Articles

Lipid Handling Induces Ferroptosis and Conveys Sensitivity to Anti-BCMA Immunotherapy in Multiple Myeloma

Enrico La Spina, Salvatore Cortellino, Cesarina Giallongo, Marisabel Mecca, Simona Picerno, Angela Amoresano, Gabriella Pinto, Stefania Serpico, Alessandro Sgambato, Grazia Scandura, Daniela Cambria, Daniele Tibullo, Antonino Neri, Francesco Di Raimondo, Alessandra Romano

Blood (2023) 142 (Supplement 1): 4682.

https://doi.org/10.1182/blood-2023-186845

Published: 2023

Journal Articles

Hells (LSH) Controls Gene Expression in T-Cell Lymphomas By Regulating RNA Polymerase II with a Bimodal Function

Valentina Fragliasso, Veronica Manicardi, Annalisa Tameni, Selene Mallia, Benedetta Donati, Federica Torricelli, Emanuele Vitale, Magda Zanelli, Stefano Luminari, Stefano Ascani, Francesca Sanguedolce, Noemi Puccio, Antonino Neri, Alessia Ciarrocchi

Blood (2023) 142 (Supplement 1): 2778.

https://doi.org/10.1182/blood-2023-177555

Published: 2023

Journal Articles

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Blood (2023) 142 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2023-188408

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

Novel Combinatorial Therapeutic Options in NEAT1-Depleted Multiple Myeloma Cells By the Integration of in Vitro and in silico Drug Screening Approaches

Noemi Puccio, Elisa Taiana, Gloria Manzotti, Elisabetta Mereu, Domenica Ronchetti, Cecilia Bandini, Ilaria Craparotta, Laura Di Rito, Marco Bolis, Veronica Manicardi, Valentina Fragliasso, Nicola Amodio, Niccolò Bolli, Stefano Luminari, Alessia Ciarrocchi, Roberto Piva, Antonino Neri

Blood (2023) 142 (Supplement 1): 6612.

https://doi.org/10.1182/blood-2023-190131

Published: 2023

Journal Articles

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Blood (2023) 141 (21): 2615–2628.

https://doi.org/10.1182/blood.2022019240

Published: 2023

Includes: Supplemental data

Journal Articles

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Blood (2023) 141 (4): 391–405.

https://doi.org/10.1182/blood.2022016892

Published: 2023

Includes: Supplemental data

Journal Articles

The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities

Debora Soncini, Pamela Becherini, Elisa Gelli, Claudia Martinuzzi, Fabio Guolo, Antonino Neri, Antonia Cagnetta, Roberto Massimo Lemoli, Michele Cea

Blood (2022) 140 (Supplement 1): 9929.

https://doi.org/10.1182/blood-2022-169453

Published: 2022

Journal Articles

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1551–1552.

https://doi.org/10.1182/blood-2022-167604

Published: 2022

Journal Articles

MGUS and Chip: Two Faces, but Not of the Same Medal

Matteo Claudio Da Via, Marta Lionetti, Antonio Matera, Erica Travaglino, Ugo Lucca, Emma Riva, Mauro Tettamanti, Luca Baldini, Antonino Neri, Matteo G. Della Porta, Niccolo Bolli

Blood (2021) 138 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2021-147890

Published: 2021

Journal Articles

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Blood (2021) 138 (Supplement 1): 2641.

https://doi.org/10.1182/blood-2021-146848

Published: 2021

Journal Articles

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Blood (2021) 138 (18): 1705–1720.

https://doi.org/10.1182/blood.2020010572

Published: 2021

Includes: Supplemental data

Journal Articles

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Blood (2021) 137 (18): 2495–2508.

https://doi.org/10.1182/blood.2020008414

Published: 2021

Includes: Supplemental data

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

Impact of Genetic Predisposition on Glyco-Metabolic Side Effects of TKIs in CML

Alessandra Iurlo, MD PhD, Veronica Resi, MD, Maria Chiara Barbanti, MD, Chiara Pesenti, Cristina Bucelli, MD, Silvia Artuso, Valeria Grancini, MD, Daniele Cattaneo, MD, Antonino Neri, MD, Monica Miozzo, MD, Emanuela Orsi, MD

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-139188

Published: 2020

Journal Articles

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88

Antonio Sacco, RN, Cinzia Federico, PhD, Arianna Giacomini, PhD, Cinzia Caprio, PhD, Federica Maccarinelli, PhD, Katia Todoerti, PhD, Vanessa Favasuli, Antonella Anastasia, MD, Marina Motta, MD, Giuseppe Rossi, MD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Antonino Neri, MD, Roberto Ronca, PhD, Chiara Cattaneo, MD, Alessandra Tucci, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MDPhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136523

Published: 2020

Journal Articles

Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma

Matteo Claudio Da Via', MD, Bachisio Ziccheddu, Matteo Dugo, Marta Lionetti, PhD, Katia Todoerti, PhD, Mattia D'Agostino, MD, Antonino Neri, MD, Luca Baldini, MD PhD, Paolo Corradini, Francesco Maura, MD, Niccolo Bolli, MD PhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-136211

Published: 2020

Journal Articles

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Blood (2020) 135 (21): 1859–1869.

https://doi.org/10.1182/blood.2019003453

Published: 2020

Includes: Supplemental data

Journal Articles

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3104.

https://doi.org/10.1182/blood-2019-124391

Published: 2019

NARROW

Lipid Handling Induces Ferroptosis and Conveys Sensitivity to Anti-BCMA Immunotherapy in Multiple Myeloma

Hells (LSH) Controls Gene Expression in T-Cell Lymphomas By Regulating RNA Polymerase II with a Bimodal Function

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Novel Combinatorial Therapeutic Options in NEAT1-Depleted Multiple Myeloma Cells By the Integration of in Vitro and in silico Drug Screening Approaches

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

MGUS and Chip: Two Faces, but Not of the Same Medal

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Impact of Genetic Predisposition on Glyco-Metabolic Side Effects of TKIs in CML

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88

Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only